financetom
Business
financetom
/
Business
/
Evercore strategists back dour S&P 500 view, expect weaker earnings outlook
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Evercore strategists back dour S&P 500 view, expect weaker earnings outlook
Apr 15, 2024 9:20 AM

NEW YORK (Reuters) - U.S. earnings estimates are likely to weaken as companies issue cautious outlooks, according to Evercore ISI strategists, who stood by their view the S&P 500 will end the year well lower than current levels.

As first-quarter reporting season gets underway, 30 S&P 500 companies have posted results so far with a 6% earnings beat, according to BofA Global Research. Stocks slumped on Friday following results from several major banks, the first big day of the quarterly reporting season.

The S&P 500 through Friday had advanced 7.4% this year, and the stability in 2024 earnings estimates has been a supportive factor for stocks, Evercore equity and derivatives strategists led by Julian Emanuel said in a note.

But that is "unlikely to persist," the strategists said.

"We believe the corporate outlooks will be more guarded, and EPS revised lower," Evercore said in a research note on Sunday.

The strategists reiterated their year-end target for the S&P 500 of 4,750, about 7% below Friday's close of 5,123.41 for the benchmark index.

Current consensus estimates for earnings are optimistic even for a "no landing" economic scenario, Evercore said.

The strategists said they were defensively positioned, including "outperform" ratings on the consumer staples, healthcare and communication services sectors, as they anticipate "intensifying volatility."

Evercore's dour outlook comes while other strategists have boosted their S&P 500 targets in recent weeks as stocks have gotten off to a strong start this year.

The Wells Fargo Investment Institute on Monday raised their year-end S&P 500 forecast to a range of 5,100-5,300, up from 4,800-5,000 previously. WFII's strategists also lifted their targets for S&P 500 earnings and U.S. economic growth in 2024.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Market Chatter: Sinclair Builds 8% Stake in E.W. Scripps
Market Chatter: Sinclair Builds 8% Stake in E.W. Scripps
Nov 17, 2025
07:13 AM EST, 11/17/2025 (MT Newswires) -- Sinclair (SBGI) has accumulated an almost 8% stake in E.W. Scripps (SSP), the Wall Street Journal reported Monday, citing a regulatory filing. Sinclair is vying to acquire the local TV broadcaster, and the position is seen as a move to push Scripps into a deal after months of constructive talks, according to the...
Sealed Air Corp to go private in $10.3 billion deal with CD&R
Sealed Air Corp to go private in $10.3 billion deal with CD&R
Nov 17, 2025
Nov 17 (Reuters) - U.S. packaging company Sealed Air Corp ( SEE ) said on Monday it will go private after being bought by private investment firm CD&R for $10.3 billion, including debt. Under the agreement, Sealed Air ( SEE ) shareholders will receive $42.15 in cash per share, a nearly 13% premium to its closing price on November 11....
Safety products maker Brady's Q1 sales beat estimates 
Safety products maker Brady's Q1 sales beat estimates 
Nov 17, 2025
Overview * Brady fiscal Q1 sales rise 7.5%, beating analyst expectations * Adjusted EPS for fiscal Q1 beats analyst expectations, rising 8% yr/yr * Company raises low end of full-year adjusted EPS guidance Outlook * Brady raises low end of fiscal 2026 Adjusted Diluted EPS guidance to $4.90-$5.15 * Brady updates fiscal 2026 GAAP EPS guidance to $4.57-$4.82 due to...
4D Molecular Therapeutics Names Kristian Humer as CFO
4D Molecular Therapeutics Names Kristian Humer as CFO
Nov 17, 2025
07:15 AM EST, 11/17/2025 (MT Newswires) -- 4D Molecular Therapeutics ( FDMT ) said Monday it has named Kristian Humer as chief financial officer. Humer has more than two decades of experience including as managing director in Citi's (C) Healthcare Investment Banking unit, the company said. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved